
==== Front
Gastro Hep Adv
Gastro Hep Adv
Gastro Hep Advances
2772-5723
Elsevier

S2772-5723(24)00073-6
10.1016/j.gastha.2024.05.006
Original Research—Basic
Lanifibranor Reduces Inflammation and Improves Dyslipidemia in Lysosomal Acid Lipase-Deficient Mice
Bradić Ivan 12†
Vujić Nemanja 1
Kuentzel Katharina B. 1‡
Habisch Hansjörg 1
Pirchheim Anita 1
Akhmetshina Alena 1
Henderson John D. 2
Madl Tobias 13§
Deshmukh Atul S. atul.deshmukh@sund.ku.dk
2∗∗
Kratky Dagmar dagmar.kratky@medunigraz.at
13∗
1 Division of Molecular Biology and Biochemistry, Gottfried Schatz Research Center, Medical University of Graz, Graz, Austria
2 Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark
3 BioTechMed-Graz, Graz, Austria
∗ Correspondence: Address correspondence to: Dagmar Kratky, PhD, Division of Molecular Biology and Biochemistry, Gottfried Schatz Research Center, Medical University of Graz, Neue Stiftingtalstrasse 6/4, Graz 8010, Austria. dagmar.kratky@medunigraz.at
∗∗ Atul S. Deshmukh, PhD, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Blegdamsvej 3B, Mærsk Tårnet, 8. sal, Copenhagen 2200, Denmark. atul.deshmukh@sund.ku.dk
† Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark.

‡ Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.

§ Otto Loewi Research Center, Medicinal Chemistry, Medical University of Graz, Graz, Austria.

28 5 2024
2024
28 5 2024
3 6 711723
4 4 2024
15 5 2024
© 2024 The Authors
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Background and Aims

Recent studies showed that patients suffering from lysosomal acid lipase deficiency (LAL-D) benefit from enzyme replacement therapy; however, liver histopathology improved in some but not all patients. We hypothesized that the pan-peroxisome proliferator-activated receptor agonist lanifibranor may have beneficial effects on liver inflammation in LAL knockout (Lal−/−) mice based on its promising results in alleviating liver inflammation in patients with metabolic dysfunction-associated steatohepatitis.

Methods

Female Lal−/− mice were daily gavaged with lanifibranor or vehicle for 21 days. The effects of the treatment were assessed by measuring body and organ weights, plasma lipids and lipoproteins, as well as hematological parameters, followed by liver proteomics and metabolomics.

Results

Lanifibranor treatment slightly altered organ weights without affecting the total body weight of Lal−/− mice. We observed major changes in the proteome, with multiple proteins related to lipid metabolism, peroxisomal, and mitochondrial activities being upregulated and inflammation-related proteins being downregulated in the livers of treated mice. Hepatic lipid levels and histology remained unaltered, whereas plasma triacylglycerol and total cholesterol levels were decreased and the lipoprotein profile of lanifibranor-treated Lal−/− mice improved.

Conclusion

Lanifibranor treatment positively affected liver inflammation and dyslipidemia in Lal−/− mice. These findings suggest the necessity of a further combined study of lanifibranor with enzyme replacement therapy in Lal−/− mice to improve the phenotype. Moreover, there is a compelling rationale for conducting clinical trials to assess the efficacy of lanifibranor as a potential treatment option for LAL-D in humans.

Graphical abstract

Keywords

LAL
Lysosomal Acid Lipase Deficiency
Liver Inflammation
Lipoproteins
Pan-PPAR Agonist
Abbreviations used in this paper

ACN acetonitrile

AST aspartate aminotransferase

CDAA-HFD choline-deficient amino acid-defined high-fat diet

ERT enzyme replacement therapy

FDR false discovery rate

HDL high-density lipoprotein

Lal−/− LAL knockout

LAL-D lysosomal acid lipase deficiency

LDL low-density lipoprotein

MASH metabolic dysfunction-associated steatohepatitis

MASLD metabolic dysfunction-associated steatotic liver disease

MS mass spectrometry

NMR nuclear magnetic resonance

PBS phosphate-buffered saline

PCA principal component analysis

PPAR peroxisome proliferator-activated receptor

TG triacylglycerol
==== Body
pmcIntroduction

Lysosomal acid lipase deficiency (LAL-D) is a lysosomal storage disorder that affects 1 in 177,452 individuals.1 It may masquerade as metabolic dysfunction-associated steatotic liver disease (MASLD) or present with cryptogenic cirrhosis.1 LAL activity is reduced in adult MASLD2,3 and even more so in metabolic dysfunction-associated steatohepatitis (MASH) and cryptogenic cirrhosis.4,5 Furthermore, a correlation was found between decreased LAL activity and the extent of liver fibrosis in pediatric patients with MASLD.6 MASLD is associated with the accumulation of high levels of fatty acids, triacylglycerols (TG), and ceramides in the liver.7 Depending on the mutations in the LIPA gene and the residual LAL activity, patients develop very severe (early-onset) or less severe (late-onset) LAL-D.8 Since LAL is the sole enzyme known to degrade cholesteryl esters and TG in the acidic lysosomal lumen, a lack of the enzymatic activity causes lysosomal accumulation of the substrates.8 In patients suffering from early-onset LAL-D, the massive ectopic lipid deposition affects multiple organs, leading to death within the first few months of life due to malabsorption, cachexia, and failure to thrive.9 In contrast, patients with late-onset LAL-D survive into adulthood and usually present with hepatosplenomegaly, dyslipidemia, and atherosclerosis.9

Similar to humans, LAL knockout (Lal−/−) mice exhibit lipodystrophy, ectopic lipid accumulation, progressive hepatosplenomegaly, and dyslipidemia.10, 11, 12 The phenotype of Lal−/− mice resembles late-onset LAL-D, despite having no residual LAL activity.10, 11, 12 Lal−/− mice were used to test various treatment approaches for LAL-D, including enzyme replacement therapy (ERT) and gene therapy.13,14 Particularly, ERT with recombinant human LAL showed promising preclinical outcomes by reducing the size of the liver and spleen and decreasing lipid accumulation in multiple tissues of Lal−/− mice.13 Currently, human LAL ERT is the most effective therapeutic strategy for LAL-D patients,8 leading to an improvement of liver injury markers and dyslipidemia.15 However, mild to moderate adverse effects were reported in the majority of treated patients.8 In addition, the impact of ERT on liver histology and inflammation is inconclusive,16 as some patients exhibited improvements, while others experienced a worsening of the liver phenotype.15 Disease severity and its specific stage, LAL-D-dependent cumulative liver injury and age, development of neutralizing antibodies against the drug, or other epigenetic factors may influence the efficacy of ERT treatment in LAL-D patients.

We recently showed that the livers of Lal−/− mice have impaired lysosomal function and decreased expression of proteins related to fatty acid metabolism and peroxisomes.17 In addition, genetic loss of LAL and pharmacological inhibition of lysosomal function18 downregulate peroxisome proliferator-activated receptor (PPAR) α signaling and decrease peroxisomal biogenesis and lipid degradation. PPARs are a family of nuclear receptors that regulate whole-body energy metabolism, inflammation, peroxisomal biogenesis, and fatty acid metabolism.19,20 Due to their distinct functions, PPARα is primarily expressed in the liver, PPARγ in adipocytes, and PPARδ is expressed ubiquitously. Single and dual PPAR agonists have shown promising results in the treatment of diabetes and MASLD-related complications.21 The pan-PPAR agonist lanifibranor combines the benefits of selective PPAR agonists by targeting all 3 PPAR isoforms and successfully reduces hepatic steatosis, inflammation, and fibrosis in MASLD mouse models.22 Treatment with lanifibranor also improved liver inflammation and might lead to regression of fibrosis in MASH patients, as evidenced by the positive impact of lanifibranor on resolution of MASH without worsening of fibrosis and the regression of fibrosis without a deterioration of MASH from the phase 2b trial.23 The lanifibranor-treated group exhibited a dropout rate of less than 5% due to adverse events, which were primarily mild or moderate in intensity. The efficacy and safety of lanifibranor in the treatment of MASH with fibrosis are currently being tested in a large multicenter phase 3 clinical trial (NCT04849728, EudraCT Number: 2020-004986-38).

The aim of the study was to investigate the potential of lanifibranor to ameliorate liver inflammation in Lal−/− mice. The results demonstrate that pan-PPAR agonism, even without ERT, significantly improved dyslipidemia and hepatic inflammation without negatively affecting liver lipid parameters in Lal−/− mice. These findings suggest that targeting PPAR signaling may be an effective approach to alleviating hepatic inflammation in LAL-D and warrant further studies to establish the therapeutic potential of lanifibranor.

Methods

Animals and Pharmacological Treatment

The mice were housed in a clean and temperature-controlled (22 ± 1 °C) environment and had unlimited access to chow diet (Altromin 1324, Lage, Germany) and water on a regular 12-hour light/12-hour dark cycle. The experiments were performed using 10 female Lal−/− mice aged 7–11 weeks on the C57BL/6J background,12 which were randomly selected. Six mice were gavaged a suspension of 1% methylcellulose and 0.1% poloxamer in water (vehicle), while 4 mice were gavaged with the vehicle suspension supplemented with 30 mg/kg of lanifibranor once daily for 21 days, which has already been described to exhibit antifibrotic activity in a liver fibrosis model.24 All treated mice were sacrificed 24 hours after the final treatment and fasted for 4 hours prior to sacrifice.

The animal experiments were conducted in accordance with the European Directive 2010/63/EU, complying with national laws, and approved by the Austrian Federal Ministry of Education, Science, and Research, Vienna, Austria (2022-0.920.281, BMWFW-66.010/0109-WF/V/3b/2015, 2022-0.861.148).

Plasma Lipid and Lipoprotein Quantification

Plasma TG and cholesterol concentrations were determined from ethylenediaminetetraacetic acid blood as previously described.17 Lipoprotein profiles were obtained after the separation of 200 μL pooled plasma by fast protein liquid chromatography (Pharmacia P-500, Uppsala, Sweden) equipped with a Superose 6 column (Amersham Biosciences, Piscataway, NJ).

Tissue Lipid Extraction and Quantification

Liver tissue was lysed in phosphate-buffered saline (PBS) using a Precellys homogenizer (Bertin Instruments, Bretonneux, France) and then centrifuged at 8000 × g for 2 minutes at 4 °C. From the supernatant, an equivalent of 20 mg of tissue was transferred into a new tube, and the volume was filled up to 100 μL with PBS. The samples were treated with 750 μL of methanol and 2.5 mL of methyl tert-butyl ether, vortexed for 10 seconds, and rotated for 1 hour. After the addition of 600 μL ddH2O, the samples were vortexed for 10 seconds and left for 10 minutes. The phases were separated by centrifugation at 2000 × g for 10 minutes. The upper organic phase was collected, to which 200 μL of 2% TritonX-100 in methanol was added before evaporation under a N2 stream. Two hundred microliters of ddH2O were added to the samples, and the precipitates were dissolved by vortexing for 20 seconds, followed by incubation in a sonication bath for 1 hour and with a tip-sonicator for 10 seconds. The lipid levels were determined as described above.

Hematoxylin and Eosin and Masson's Trichrome Staining

Fresh liver tissue was fixed in 4% PBS-buffered paraformaldehyde for 24 hours and embedded in paraffin. Slides with deparaffinized tissue sections were incubated with hematoxylin for 10 minutes and then with eosin for 1 minute. Masson's trichrome staining was performed as previously described.25

Measurement of Liver Injury Marker

Freshly isolated heparinized blood was centrifuged for 7 minutes at 5200 × g and 4 °C, and plasma was collected. Alanine aminotransferase and aspartate aminotransferase (AST) concentrations in plasma were analyzed with Fuji Dri-Chem NX500 (FUJIFILM Holdings Corporation, Tokyo, Japan).

Measurement of Hematological Parameters and Blood Glucose

Blood samples were collected in ethylenediaminetetraacetic acid-coated tubes and analyzed using the V-Sight Vet Hematology Analyzer (A. Menarini Diagnostics, Florence, Italy) according to the manufacturer's protocol.

Glucose was measured from a drop of tail vein blood using a glucometer (AccuCheck, Roche Holding AG, Basel, Switzerland).

Sample Preparation for Mass Spectrometry-Based Proteomics and Measurement

One milliliter of sodium dodecyl sulfate buffer (0.1 M Tris-HCl, pH 8.5%, and 4% sodium dodecyl sulfate) was added to approximately 100 mg liver tissue from Lal−/− mice. Samples were homogenized in a BeatBox tissue homogenizer (PreOmics GmbH; Martinsried, Germany) at 850 rpm and boiled for 10 minutes at 95 °C. Lysates were sonicated using a tip-sonicator and centrifuged at 16,000 × g for 10 minutes. Protein concentrations were determined in the supernatant using the DC Protein Assay (Bio-Rad Laboratories, Hercules, CA). Proteins were reduced and alkylated with final concentrations of 10 mM tris(2-carboxyethyl)phosphine and 50 mM 2-chloroacetamide. Proteins were digested using the protein aggregation capture method26 on a KingFisher Flex robot (Thermo Fisher Scientific, Waltham, MA) in 96-well format. Briefly, magnetic hydroxyl beads (ReSyn Biosciences, Gauteng, South Africa) were mixed with 30 μg protein lysate 1:4 (w:w) in the 96-well plate. A digestion solution containing endoproteinases LysC (1:500, w:w) and trypsin (1:100, w:w) was added to the second 96-well plate. Five additional 96-well plates containing 500 μL 100% acetonitrile (ACN), 700 μL 100% ACN, 1 mL 100% ACN, 1 mL 100% ethanol, and 1 mL 100% ethanol, respectively, were prepared. An in-house program was used to digest the samples. Peptides were purified with 3 × C18 StageTips.27 EvoTips (Evosep, Odense, Denmark) were loaded with 200 ng of purified peptides, which were then separated on a 15-cm column with 150 μM ID packed with C18 beads (1.9 μm) (Pepsep) using Evosep ONE HPLC. The separated peptides were injected into a timsTOF Pro 2 mass spectrometer (Bruker Daltonics, Bremen, Germany) operated in diaPASEF mode, utilizing a CaptiveSpray ionization source with a 20-μm emitter. Mass spectrometry (MS) data were collected between 100 and 1700 m/z. Each MS/MS data acquisition was performed with diaPASEF cycle of 1.8 s and covered ion mobility range between 1.6 and 0.6 1/K0. Ion mobility was calibrated with 622.0289, 922.0097, and 1221.9906 Agilent ESI-L Tuning Mix ions. For diaPASEF, a long gradient with 10 diaPASEF scans with 3 25 Da windows per ramp, a mass range between 400 and 1201 Da, and a mobility range between 1.43 and 0.6 1/K0 was used. The collision energy parameters were set to 59 eV at 1/K0 = 1.3 and linearly decreased to 20 eV at 1/K0 = 0.85 Vs cm−2 during the measurement. Accumulation time and PASEF ramp time were 100 ms.

Proteomics Data Quantification and Bioinformatics

Protein quantification was performed with DIA-NN (1.8.1),28,29 with raw data searched against the Mouse Uniprot reviewed FASTA file downloaded on August 09, 2021 with the following parameters: FASTA digest for library-free search/library generation, deep learning-based spectra, retention time, and ion mobility spectra prediction. Trypsin-digested peptides with up to 2 missed cleavages were accepted, along with 3 variable modifications: N-terminal methionine excision, cysteine carbamidomethylation, and methionine oxidation. The default peptide parameters were 7–30 for the peptide length range, 1–4 for the precursor charge range, 300–1800 for the precursor m/z range, and 200–1800 for the fragment ion m/z range. The precursor false discovery rate (FDR) was set to 1%, mass accuracy to 10 ppm, and MS1 accuracy to 20 ppm. Isotopologues were used in the search, along with match between runs, heuristic protein inference (protein inference was set to genes), and exclusion of shared spectra. Searches were conducted in double-pass mode using a robust, high-precision liquid chromatography quantification strategy, with cross-run normalization as a function of retention time and smart profiling for library generation. Data were analyzed using Perseus (1.6.15.0)30 and Jupyter Notebook with Python 3.9. Protein intensities were log2 transformed before filtering the data for 70% of valid values in at least 1 group. Data were imputed to fill missing abundance values by drawing random numbers from a Gaussian distribution with a standard deviation of 30% and a downshift of 1.8 standard deviations from the mean relative to that of the proteome abundance distribution. Principal component analysis (PCA) was performed on the z-scored data in Python utilizing the packages Pandas, Matplotlib, Numpy, Seaborn, Sklearn, and Bioinfokit. Statistically significant changes were determined by a t-test with S0 = 0.1 and FDR = 0.05. Reactome pathway enrichment with the PANTHER Overrepresentation Test29,30 was performed using 2 clusters representing significantly increased proteins in the livers of lanifibranor- or vehicle-treated Lal−/− mice. KEGG pathway enrichment was performed with z-scored intensities from significantly changed proteins using Pathview.31,32 PPAR signaling was selected from enriched KEGG pathways and changed proteins related to it were counted and visualized. The number of significantly upregulated proteins from livers of vehicle- and lanifibranor-treated mice associated with specific UniProt keywords was determined by counting annotated proteins (Swiss-Prot) from relevant UniProt keywords.

Protein matrix, enriched Reactome pathways, and proteins related to specific UniProt keywords are listed in Table A1.

Nuclear Magnetic Resonance (NMR) Metabolomics

Metabolomics analysis by NMR spectroscopy was performed as previously described.33 Briefly, 20 mg of liver tissue was mixed with a solution of ice-cold methanol and high-purity H2O (2:1) to inhibit enzymatic processes and precipitate proteins. Samples were homogenized 2 times for 20 seconds using a Precellys 24 tissue homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France) in tubes containing Precellys beads (1.4 mm zirconium oxide beads, Bertin Technologies). Next, samples were centrifuged at 9703 × g for 30 minutes at 4 °C, the supernatants were transferred to new tubes and lyophilized at <1 Torr, 824 × g, 25 °C for 10 hours in a vacuum-drying chamber (Savant Speedvac SPD210 vacuum concentrator) with an attached cooling trap (Savant RVT450 refrigerated vapor trap) and vacuum pump (VLP120) (Thermo Scientific, Waltham, MA). Samples were redissolved in 500 μL NMR buffer consisting of D2O, 0.08 M Na2HPO4, 4.6 mM 3-(trimethylsilyl) propionic acid-2,2,3,3-d4 sodium salt (TSP), and 0.04 (w/v)% NaN3 (pH adjusted to 7.4 with HCl and NaOH) and transferred to 5-mm NMR tubes. NMR spectroscopy was carried out using a Bruker Avance Neo 600 MHz spectrometer coupled to a TXI probe head at 310 K. 1H 1D NMR spectra were obtained using the Carr–Purcell–Meiboom–Gill (CPMG) pulse sequence (cpmgpr1d, 128 scans, 73,728 points in F1, 12,019.230 Hz spectral width, recycle delay 4 seconds) with a pre-saturation for water suppression. NMR spectra processing, including Fourier transformation of the free induction decay, automatic phasing, and baseline correction, was done using Bruker Topspin software version 4.0.2. A Matlab script (software version 2014b) was used for importing the spectra. The peaks surrounding the water, TSP, and methanol signals were eliminated, the NMR spectra were aligned,34 and a probabilistic quotient normalization35 was carried out. Chenomx NMR Suite 8.4 (Chenomx Inc, Edmonton, AB, Canada), the human metabolome database,36 and reference chemicals were used to identify metabolites. Metabolites were quantified by signal integration of the normalized spectra. For each metabolite, a representative peak with no overlapping signals was determined. The start and end points of the integration were then selected to revolve around this peak, and the areas of all peaks were integrated for all samples and metabolites using an R script (RStudio 2023 with R version 4.1.3) and provided as arbitrary units (a.u.) proportional to the concentration of the respective analyte. MetaboAnalyst 5.037 was used to calculate univariate statistics (shown as volcano plot). An unpaired 2-tailed Student's t-test with Benjamini-Hochberg correction was used to calculate the significance of metabolite levels between controls and lanifibranor-treated mice. Since none of the metabolites revealed an FDR <0.05, uncorrected P values were plotted. For multivariate statistics, PCA and orthogonal partial least squares discriminant analysis were calculated. The statistical significance of the multivariate model was verified by permutation testing of the quality evaluation statistic Q2, which was barely significant (P = .11).

Statistics

Data analysis and statistics for proteomics and metabolomics data are described in the sections above. For other experiments, comparisons between groups were performed using the unpaired 2-tailed Student's t-test in GraphPad Prism 9.5.1. Data are presented as mean or as mean ± SD. Significance levels were set to: ∗P < .05, ∗∗P ≤ .01, ∗∗∗P ≤ .001, and ∗∗∗∗P ≤ .0001.

Results

Lanifibranor Treatment Causes Minor Changes in Organ Weight but Not Body Weight in Lal−/− Mice

We assessed the effects of lanifibranor treatment on the phenotype of female Lal−/− mice after 21 days of daily gavage with vehicle or lanifibranor (Figure 1A). The body weight of both groups was comparable (Figure 1B). The tissue-to-body weight ratio of liver, heart, small intestine, and brown adipose tissue was increased in lanifibranor-treated mice by 1.12, 1.32, 1.21, and 1.49 fold, respectively, whereas the ratio of subcutaneous white adipose tissue and spleen remained unchanged (Figure 1C). We next measured several hematologic parameters to determine the functional consequences of increased liver and heart weight in lanifibranor-treated mice but observed no changes in platelet number (Figure A1A), red blood cell number (Figure A1B), and hemoglobin levels (Figure A1C).Figure 1 Lanifibranor treatment causes minor changes in organ weight but not body weight in lysosomal acid lipase (LAL) knockout (Lal−/−) mice. (A) Lal−/− mice were daily gavaged with a suspension of methylcellulose (1%) and poloxamer (0.1%) in water (vehicle) with or without 30 mg/kg lanifibranor for 21 days (created with BioRender.com). (B) Body weight and (C) ratio of tissue weight to body weight of lanifibranor- or vehicle-treated Lal−/− mice. Data represent mean values ± SD (n = 4–6), and statistical significance was determined by 2-tailed Student's t-tests. ∗P < .05, ∗∗P ≤ .01, ∗∗∗∗P ≤ .0001. BAT, brown adipose tissue; sWAT, subcutaneous white adipose tissue.

Lanifibranor Treatment Activated the PPAR Signaling Pathway in the Livers of Lal−/− Mice

To identify potential changes in protein expression following lanifibranor treatment, we performed untargeted label-free quantitative proteomic analysis on livers of lanifibranor- and vehicle-treated Lal−/− mice. The distinct clustering pattern of the data by PCA indicated differences between the 2 groups, with principal component 1 (PC1) explaining 39.3% and PC2 explaining 18.9% of the variance (Figure 2A). The abundance of 6151 quantified proteins covered 4 orders of magnitude, and the detection of multiple PPAR target proteins (Figure 2B) demonstrated the good quality of the proteomics data. Of the 510 significantly changed proteins, 256 were upregulated and 254 were downregulated in the livers of lanifibranor-treated Lal−/− mice (Figure 2C), indicating substantial remodeling of the proteome following treatment. The highest upregulated proteins included acyl-coenzyme A thioesterase 1 (ACOT1), peroxisomal bifunctional enzyme (EHHADH), cytochrome P450 4A14 (CYP4A14), CYP4A10, and ankyrin repeat and SOCS box containing 6 (ASB6), whereas peptidoglycan recognition protein 1 (PGLYRP1), ras-related protein Rab-3C (RAB3C), tubulin beta 4A class IVa (TUBB4A), serine/threonine-protein kinase PLK1 (PLK1), and laminin subunit alpha 1 (LAMA1) were among the 5 most downregulated proteins (Figure 2C). Of the 43 proteins annotated to the KEGG PPAR signaling pathway, 18 were upregulated in the livers of lanifibranor-treated mice, whereas none was upregulated in control livers (Figure 2D). The z-scored intensities of the upregulated proteins involved in PPAR signaling clearly demonstrated that treatment with the pan-PPAR agonist lanifibranor successfully triggered the expression of multiple PPAR targets, with the most pronounced effects on CYP4A10, EHHADH, and peroxisomal acyl-coenzyme A oxidase 1 (ACOX1) (Figure 2E).Figure 2 Lanifibranor increased the expression of peroxisome proliferator-activated receptor (PPAR) signaling-associated proteins. (A) Plot of principal component analysis (PCA) and (B) the dynamic range of the quantified liver proteome with some PPAR target proteins upregulated in the livers of lanifibranor-treated Lal−/− mice. (C) The volcano plot displays 254 significantly increased and 246 significantly decreased proteins in the livers of lanifibranor-treated Lal−/− mice. (D) The number of significantly changed proteins associated with the KEGG PPAR signaling pathway and (E) their heatmap representing all significantly altered proteins annotated in the livers of vehicle- or lanifibranor-treated Lal−/− mice (n = 4–6). Statistical significance was determined by 2-tailed Student's t-tests with permutation-based FDR (FDR < 0.05, S0 = 0.1).

Functional Interpretation of Activated PPAR Signaling

To functionally interpret the lanifibranor-induced proteome changes, we performed an overrepresentation analysis on 2 clusters representing significantly upregulated and downregulated proteins in livers of lanifibranor-treated Lal−/− mice (Figure 3A). Numerous Reactome pathways were enriched, including fatty acid beta-oxidation, peroxisomal lipid metabolism, peroxisomal protein import, cholesterol biosynthesis, and lipid metabolism (Figure 3B). In contrast, immune system and signal transduction were among the pathways that were less enriched, indicating decreased inflammation in the livers of lanifibranor-treated mice (Figure 3B). Consistent with this finding, several inflammation-related Reactome pathways, including neutrophil degranulation and (innate) immune system, were enriched in control livers (Figure 3C). Extracellular matrix organization was the most enriched Reactome pathway in control livers, suggesting a profound impact of lanifibranor on extracellular matrix remodeling (Figure 3C). These data indicated that lanifibranor stimulated various processes related to lipid metabolism and peroxisomes and exhibited a favorable impact on liver inflammation in Lal−/− mice.Figure 3 Treatment with lanifibranor induces peroxisome and lipid metabolism-related pathways in the livers of Lal−/− mice. (A) Heatmap of z-scored significantly changed proteins in the livers of lanifibranor- and vehicle-treated Lal−/− mice. (B) The highest significantly enriched Reactome pathways of proteins significantly upregulated and (C) downregulated in the livers of lanifibranor-treated Lal−/− mice. Data represent n = 4–6. Statistical significance was determined by (A) 2-tailed Student's t-tests with permutation-based FDR (FDR < 0.05, S0 = 0.1) and (B and C) by Fisher's exact with Benjamini-Hochberg correction (FDR < 0.05).

Lanifibranor Treatment Affects the Liver Proteome of Peroxisomes, Mitochondria, Lipid Metabolism, and Extracellular Matrix Proteins

To further scrutinize the proteomic changes induced by lanifibranor treatment, we quantitated the number of significantly dysregulated proteins annotated to specific UniProt keywords in the livers of lanifibranor- and vehicle-treated Lal−/− mice. Administration of lanifibranor triggered the upregulation of 44 proteins associated with peroxisomes, 74 with mitochondria, 12 with electron transport, and 92 with lipid metabolism (Figure 4A). In contrast, livers of control mice had only 2, 13, 0, and 7 significantly upregulated proteins associated with peroxisomes, mitochondria, electron transport, and lipid metabolism, respectively (Figure 4A). Increased abundance of 3-ketoacyl-CoA thiolase B, peroxisomal (ACAA1B), ACOT4, long-chain fatty acid CoA ligase 6 (ACSL6), peroxisomal membrane protein 11A (PEX11A), and peroxisomal acyl-CoA oxidase 1 (ACOX1) indicated elevated peroxisomal biogenesis and fatty acid oxidation (Figure 4B). Mitochondrion-related upregulated proteins included long-chain fatty acid CoA ligase 1 (ACSL1), optic atrophy 3 protein homolog (OPA3), and mitochondrial pyruvate carrier 1 (MPC1) (Figure 4C). In addition, several proteins important for oxidative phosphorylation, including cytochrome b5 type B (MT-CYB), cytochrome b-c1 complex subunit 6 (UQCRH), and NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3 (NDUFA3) were upregulated following lanifibranor treatment (Figure 4D), confirming that pan-PPAR agonism enhanced processes related to peroxisomes and mitochondria. Most of the highest upregulated proteins related to lipid metabolism were also peroxisomal proteins (Figure 4E), further substantiating the efficacy of lanifibranor in triggering the expression of peroxisomal proteins. Notably, lanifibranor decreased the expression of multiple fibrosis-related extracellular matrix proteins, such as collagen alpha-2(I) chain (COL1A2) and collagen alpha-1(XIV) chain (COL14A1) (Figure 4F). Thus, lanifibranor upregulated proteins of lipid metabolism and downregulated proteins associated with fibrosis.Figure 4 Lanifibranor treatment triggers the expression of proteins associated with peroxisomes, mitochondria, and lipid metabolism in the livers of Lal−/− mice. (A) The number of significantly changed proteins annotated to specific UniProt keywords in the livers of vehicle- or lanifibranor-treated Lal−/− mice. Heatmaps representing the most upregulated proteins in the livers of lanifibranor-treated Lal−/− mice annotated to (B) peroxisome, (C) mitochondrion, (D) electron transport, and (E) lipid metabolism. (F) Heatmap showing the most downregulated proteins annotated to the extracellular matrix. Data represent n = 4–6. Statistical significance was determined by 2-tailed Student's t-tests with permutation-based FDR (FDR < 0.05, S0 = 0.1).

Lanifibranor Treatment Has a Minor Impact on Liver Lipid Levels and Histology

Despite the observed upregulation of 92 proteins related to lipid metabolism (Figure 4A), hepatic TG, total and free cholesterol as well as cholesteryl ester concentrations remained unaltered (Figure 5A–D). Liver histology was unchanged, as evidenced by hematoxylin and eosin staining (Figure 5E) and comparable hepatic collagen content (Figure 5E), suggesting that despite significant proteome changes, lanifibranor treatment had little effect on hepatic steatosis and pathohistology.Figure 5 Unaltered liver lipid levels and histology after lanifibranor treatment of Lal−/− mice. Concentrations of hepatic (A) triacylglycerols (TG), (B) total cholesterol (TC), (C) free cholesterol (FC), and (D) cholesteryl esters (CE) in vehicle- and lanifibranor-treated Lal−/− mice. Data represent means ± SD (n = 4). Statistical significance was determined by 2-tailed Student's t-tests. (E) Liver hematoxylin and eosin (H&E) (top row) and Masson's trichrome staining (bottom row).

To gain further insight into the consequences of lanifibranor treatment on hepatic metabolism, we performed a targeted metabolomic analysis, which revealed obvious changes in the liver metabolome upon pan-PPAR agonist treatment (Figure 6A). To determine whether metabolites differed significantly between lanifibranor-treated and control livers and to identify the metabolites primarily contributing to this difference, we applied multivariate orthogonal partial least squares discriminant analysis. This revealed a clear distinction between the groups (Figure 6B). Metabolites with increased hepatic concentrations upon treatment (filtered by their high score in the variable of importance during projection analysis) included glycerophosphocholine, alanine, glutamine, acetic acid, niacinamide, and glutathione (Figure 6C). In contrast, fumaric acid, phosphorylcholine, aspartic acid, dimethylamine, creatine, lysine, glutamic acid, formic acid, and malic acid were among the metabolites that were decreased in lanifibranor-treated Lal−/− livers (Figure 6C). These data suggest that lanifibranor treatment markedly affects the metabolome in the liver of Lal−/− mice.Figure 6 Treatment with lanifibranor leads to changes in liver metabolite concentrations in Lal−/− mice. (A) Volcano plot of metabolites with different abundances in the livers of vehicle- and lanifibranor-treated Lal−/− mice. (B) Orthogonal partial least squares discriminant analysis (O-PLS-DA) plot of liver metabolites and (C) ranking of metabolites based on the variable importance during projection (VIP) score. Data represent n = 4–5. (A) Statistical significance was determined by 2-tailed Student's t-tests with Benjamini-Hochberg correction (raw P value was plotted).

Improved Inflammation and Dyslipidemia Following Lanifibranor Treatment

Since the considerable changes in the proteome could not be explained by minor changes in liver lipid levels and histology, we tested whether treatment with the pan-PPAR agonist affected circulating lipid concentrations or systemic inflammation. We observed a trend toward lower plasma alanine aminotransferase (Figure 7A) and significantly decreased plasma AST levels (Figure 7B), indicating a reduction in hepatocellular damage. A marked reduction in circulating white blood cell (Figure 7C) and monocyte (Figure 7D) numbers suggested a beneficial impact of activated PPAR signaling on systemic inflammation. Finally, we examined the response of circulating lipid levels to lanifibranor treatment and observed decreased plasma TG and TC concentrations (Figure 7E) coupled with a reduction in low-density lipoprotein (LDL)-TC and an increase in high-density lipoprotein (HDL)-TC content. In contrast, blood glucose levels remained comparable (Figure A1D). These data indicate that lanifibranor attenuates liver and systemic inflammation while simultaneously improving dyslipidemia in Lal−/− mice.Figure 7 Lanifibranor treatment reduced liver inflammation and improved dyslipidemia in Lal−/− mice. Circulating levels of (A) alanine aminotransferase (ALT) and (B) aspartate aminotransferase (AST) in vehicle- and lanifibranor-treated Lal−/− mice. Number of (C) white blood cells (WBC) and (D) monocytes (MON), (E) plasma TG and TC concentrations, and (F) lipoprotein distribution in pooled samples from vehicle- and lanifibranor-treated Lal−/− mice. Data represent means ± SD (n = 4–6). ∗P < .05, ∗∗P ≤ .01. Statistical significance was determined by 2-tailed Student's t-tests.

Discussion

Lanifibranor showed promising results in a phase 2b study in the treatment of patients with active MASH.23 Of the 247 patients enrolled in this study, 166 received either 1200 or 800 mg of lanifibranor once daily for 6 months and 81 patients were given placebo.23 The incidence of nausea, diarrhea, peripheral edema, anemia, and weight gain of approximately 3% occurred more frequently in the lanifibranor groups than in the placebo group. One patient developed mild heart failure, which was not attributable to the treatment. The results of this trial also indicated the potential for benefits with lanifibranor with respect to several secondary end points, including hepatic fibrosis, lipid profile, and glycemic control.23 An ongoing phase 3 clinical trial (NCT04849728) will further elucidate potential adverse effects. While lanifibranor has not yet been studied as a treatment option for LAL-D, it is plausible that it could offer therapeutic benefits, given the observed similarity in liver inflammation between patients with LAL-D and MASLD.8 The proteomic analysis confirmed that treatment with lanifibranor activated the PPAR signaling pathway in Lal−/− mice, with enriched terms related to fatty acid oxidation, peroxisomal biogenesis, and lipid metabolism. PEX11A and PEX7 were among the most upregulated peroxisome-related proteins and are essential for proper peroxisomal function and the prevention of dyslipidemia and obesity.38,39 The upregulated mitochondrial protein OPA3 is a crucial regulator of mitochondrial function,40 whereas the expression levels of ACSL1 and MPC1 are directly correlated with hepatic steatosis.41,42 However, counteracting the upregulation of proteins related to lipid metabolism, mitochondrial function, and fatty acid oxidation may have a superior effect, as these processes are impaired in Lal−/− compared to control mice.17 Following lanifibranor treatment, major components of oxidative phosphorylation were also upregulated, leading to a reduction in fumaric and malic acid, suggesting an increase in mitochondrial respiration. Consistent with several studies showing a favorable effect of pan-PPAR agonism on liver steatosis, inflammation, and fibrosis in mouse and rat models,22,24,43,44 lanifibranor decreased the expression of various fibrosis-related proteins in the livers of Lal−/− mice. In addition, the treatment increased the expression of glutathione, while reducing the concentration of circulating AST. This finding indicates that the reduced expression of proteins related to inflammation and fibrosis resulted in improved liver injury. Thus, despite the distinct pathologies of LAL-D and MASLD, lanifibranor has a beneficial effect on liver inflammation.

Lanifibranor treatment decreases hepatic TG concentrations in mice fed choline-deficient amino acid-defined high-fat diet (CDAA-HFD), high-fat/high-sucrose diet, and methionine-choline-deficient diet.22,44 In Lal−/− mice, lipids accumulate in lysosomes due to the absence of LAL.8 Consequently, these lipids cannot be mobilized, unlike lipids in cytosolic lipid droplets from livers affected by MASLD.45 Therefore, the reason why lanifibranor cannot alter TG and TC levels in the livers of Lal−/− mice may be due to the predominant accumulation of lipids within lysosomes and loss of a functional enzyme to degrade them upstream of the functional consequences of pan-PPAR agonism. Lipids accumulate in the livers of Lal−/− mice during the first weeks of life46 and starting lanifibranor treatment earlier may have a more pronounced impact on lipid metabolism and inflammation. For instance, feeding 5-week-old Lal−/− mice with a fenofibrate-enriched diet for 4 weeks reduced liver TC levels but did not affect TG concentration.12

Compared to the lanifibranor-promoted weight gain in MASH patients,23 the body weight of Lal−/− mice remained unchanged. However, lanifibranor treatment slightly increased the ratios of heart and liver to body weight in Lal−/− mice. In contrast, lanifibranor treatment reduced the liver-to-body weight ratio in WT mice fed a CDAA-HFD.24 However, it had no impact on body or liver weight in a rat model of liver cirrhosis43 or heart weight in rats24 and Alms1 mutant foz/foz mice. Heart weight was not discussed in other diet-induced models of MASLD.44 The phase 2b trial also showed no increase in heart-related complications in patients treated with lanifibranor.23 However, clinical trials have rarely assessed cardiovascular outcomes due to limited power in detecting the potential cardiovascular benefits of PPAR agonist treatment in MASLD patients.47 It would therefore be necessary to determine the influence of lanifibranor on heart weight and pathophysiology in various mouse models of MASLD. Despite an increased liver and heart weight relative to body weight in Lal−/− mice after lanifibranor treatment, spleen weight remained unchanged and no adverse effects on hematological parameters were observed. The slight increase in liver and heart weight in Lal−/− mice, without any changes in liver lipids and histology, might be attributed to the distinct pathophysiology present in LAL-D mice compared to genetic or diet-induced MASLD mouse and rat models. As lipid accumulation in LAL-D mice is already evident in the first few weeks of life,46 it is possible that young mice may exhibit signs of liver inflammation. Consequently, initiating treatment with lanifibranor at an earlier stage and/or a combination of lanifibranor with ERT may result in improved liver histology in LAL-D mice. Studies using lanifibranor in various animal models should also aim to assess organ weights to account for possible side effects of the treatment.

The decreased numbers of white blood cell and monocytes in lanifibranor-treated Lal−/− mice indicate decreased systemic inflammation, consistent with the known ability of PPAR signaling to modulate inflammation and macrophage infiltration.48 In addition, lanifibranor demonstrated a positive effect on plasma lipids by reducing TG and TC concentrations. This effect was also observed in control mice fed high-fat/high-sucrose diet, CDAA-HFD, western-type diet, methionine choline-deficient diet, in a mouse model of CCl4-induced liver fibrosis,22,44 as well as in MASH patients.23 To our knowledge, the consequences of lanifibranor treatment on plasma cholesterol levels in mouse models of MASLD or liver fibrosis have not been investigated. We also found an improved distribution of plasma lipoproteins following lanifibranor treatment, with decreased LDL-cholesterol and increased HDL-cholesterol levels. Similarly, HDL-cholesterol levels improved in lanifibranor-treated MASH patients, whereas LDL-cholesterol remained unchanged.23

In conclusion, the treatment with lanifibranor improved plasma levels of liver injury markers and lipid parameters, as well as lipoprotein distribution. Furthermore, it reduced the expression of various inflammation- and fibrosis-related proteins in the livers of Lal−/− mice. These findings suggest potential additive effects of lanifibranor to ERT that should be explored in future studies, as emphasized above.

Supplementary Materials

Table A1

Figure A1 Unchanged hematological parameters and blood glucose levels after lanifibranor treatment in Lal−/− mice. Values of (A) platelets (PLT), (B) red blood cells (RBC), (C) hemoglobin (HGB), (D) blood glucose in vehicle- or lanifibranor-treated Lal−/− mice. Data represent n = 4–6.

Acknowledgments:

The authors thank A. Absenger and M. Singer for mice care, and S. Rainer and A. Ibovnik for technical assistance (all Medical University of Graz, Austria). The graphical abstract and Figure 1A were created with BioRender.com.

Authors' Contributions:

Ivan Bradić: Conceptualization, formal analysis, investigation, methodology, writing original draft, writing review and editing. Nemanja Vujić: Investigation, methodology, writing review and editing. Katharina B. Kuentzel: Investigation, methodology, writing review and editing. Hansjörg Habisch: Formal analysis, investigation, methodology, writing review and editing. Anita Pirchheim: Investigation. Alena Akhmetshina: Investigation. John D. Henderson: Investigation, methodology, writing review and editing. Tobias Madl: Methodology, writing review and editing, resources, funding acquisition. Atul S. Deshmukh: Methodology, writing review and editing, resources, funding acquisition, supervision. Dagmar Kratky: Conceptualization, writing review and editing, resources, funding acquisition, supervision. All authors had access to the study data and had reviewed and approved the final manuscript.

Conflicts of Interest: The authors disclose no conflicts.

Funding: This research was funded by the 10.13039/501100002428 Austrian Science Fund (FWF) (SFB 10.55776/F73 , DK-MCD 10.55776/W1226 , 10.55776/P32400 , 10.55776/P30882 , 10.55776/P27070 , 10.5576/P28854 , 10.5576/I3792 , 10.5576/DOC-130 ), the 10.13039/501100009818 Province of Styria , the City of Graz, 10.13039/501100019802 BioTechMed-Graz , the 10.13039/501100004955 Austrian Research Promotion Agency (FFG) (864690 and 870454 ), the Integrative Metabolism Research Center Graz, the Austrian Infrastructure Program 2016/2017, the flagship project “VascHealth,” and the Ph.D. program “Molecular Medicine” of the 10.13039/501100010109 Medical University of Graz . Mass spectrometry analyses were performed by the Proteomics Research Infrastructure at the University of Copenhagen, supported by the 10.13039/501100009708 Novo Nordisk Foundation (NNF) (NNF19SA0059305 ). This work was supported by an unconditional donation from the NNF to 10.13039/501100009708 NNF Center for Basic Metabolic Research (NNF18CC0034900 ). For open access purposes, the authors have applied a CC BY public copyright license to any author accepted manuscript version arising from this submission.

Ethical Statement: No human samples were used. The animal experiments were conducted in accordance with the European Directive 2010/63/EU, complying with national laws and approved by the Austrian Federal Ministry of Education, Science, and Research, Vienna, Austria (2022-0.920.281, BMWFW-66.010/0109-WF/V/3b/2015, 2022-0.861.148).

Data Transparency Statement: Data are available on request. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD047957 (https://www.ebi.ac.uk/pride/archive?keyword=PXD045665).

Reporting Guidelines: ARRIVE.

Material associated with this article can be found, in the online version, at https://doi.org/10.1016/j.gastha.2024.05.006.
==== Refs
References

1 Carter A. Brackley S.M. Gao J. The global prevalence and genetic spectrum of lysosomal acid lipase deficiency: a rare condition that mimics NAFLD J Hepatol 70 1 2019 142 150 30315827
2 Baratta F. Pastori D. Del Ben M. Reduced lysosomal acid lipase activity in adult patients with non-alcoholic fatty liver disease EBioMedicine 2 7 2015 750 754 26288848
3 Shteyer E. Villenchik R. Mahamid M. Low serum lysosomal acid lipase activity correlates with advanced liver disease Int J Mol Sci 17 3 2016 312 26927097
4 Baratta F. Pastori D. Ferro D. Reduced lysosomal acid lipase activity: a new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease? World J Gastroenterol 25 30 2019 4172 4180 31435171
5 Gravito-Soares M. Gravito-Soares E. Gomes D. Lysosomal acid lipase: can it be a new non-invasive serum biomarker of cryptogenic liver fibrosis and cirrhosis? Ann Hepatol 18 1 2019 78 88 31113613
6 Selvakumar P.K. Kabbany M.N. Lopez R. Reduced lysosomal acid lipase activity - a potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients Dig Liver Dis 48 8 2016 909 913 27198736
7 Carotti S. Aquilano K. Valentini F. An overview of deregulated lipid metabolism in nonalcoholic fatty liver disease with special focus on lysosomal acid lipase Am J Physiol Gastrointest Liver Physiol 319 4 2020 G469 G480 32812776
8 Korbelius M. Kuentzel K.B. Bradic I. Recent insights into lysosomal acid lipase deficiency Trends Mol Med 29 6 2023 425 438 37028992
9 Pericleous M. Kelly C. Wang T. Wolman's disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency Lancet Gastroenterol Hepatol 2 9 2017 670 679 28786388
10 Du H. Duanmu M. Witte D. Targeted disruption of the mouse lysosomal acid lipase gene: long-term survival with massive cholesteryl ester and triglyceride storage Hum Mol Genet 7 9 1998 1347 1354 9700186
11 Du H. Heur M. Duanmu M. Lysosomal acid lipase-deficient mice: depletion of white and brown fat, severe hepatosplenomegaly, and shortened life span J Lipid Res 42 4 2001 489 500 11290820
12 Radovic B. Vujic N. Leopold C. Lysosomal acid lipase regulates VLDL synthesis and insulin sensitivity in mice Diabetologia 59 8 2016 1743 1752 27153842
13 Du H. Schiavi S. Levine M. Enzyme therapy for lysosomal acid lipase deficiency in the mouse Hum Mol Genet 10 16 2001 1639 1648 11487567
14 Lam P. Ashbrook A. Zygmunt D.A. Therapeutic efficacy of rscAAVrh74.miniCMV.LIPA gene therapy in a mouse model of lysosomal acid lipase deficiency Mol Ther Methods Clin Dev 26 2022 413 426 36092360
15 Burton B.K. Sanchez A.C. Kostyleva M. Long-term sebelipase alfa treatment in children and adults with lysosomal acid lipase deficiency J Pediatr Gastroenterol Nutr 74 6 2022 757 764 35442238
16 Malinová V. Balwani M. Sharma R. Sebelipase alfa for lysosomal acid lipase deficiency: 5-year treatment experience from a phase 2 open-label extension study Liver Int 40 9 2020 2203 2214 32657505
17 Bradić I. Liesinger L. Kuentzel K.B. Metabolic changes and propensity for inflammation, fibrosis, and cancer in livers of mice lacking lysosomal acid lipase J Lipid Res 2023 100427
18 Tan H.W.S. Anjum B. Shen H.M. Lysosomal inhibition attenuates peroxisomal gene transcription via suppression of PPARA and PPARGC1A levels Autophagy 15 8 2019 1455 1459 31032705
19 Berthier A. Johanns M. Zummo F.P. PPARs in liver physiology Biochim Biophys Acta Mol Basis Dis 1867 5 2021 166097
20 Varga T. Czimmerer Z. Nagy L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation Biochim Biophys Acta 1812 8 2011 1007 1022 21382489
21 Lange N.F. Graf V. Caussy C. PPAR-targeted therapies in the treatment of non-alcoholic fatty liver disease in diabetic patients Int J Mol Sci 23 8 2022 4305 35457120
22 Lefere S. Puengel T. Hundertmark J. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆ J Hepatol 73 4 2020 757 770 32360434
23 Francque S.M. Bedossa P. Ratziu V. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH N Engl J Med 385 17 2021 1547 1558 34670042
24 Boubia B. Poupardin O. Barth M. Design, synthesis, and evaluation of a novel series of indole sulfonamide peroxisome proliferator activated receptor (PPAR) alpha/gamma/delta triple activators: discovery of lanifibranor, a new antifibrotic clinical candidate J Med Chem 61 6 2018 2246 2265 29446942
25 Vujic N. Porter Abate J. Schlager S. Acyl-CoA:Diacylglycerol acyltransferase 1 expression level in the hematopoietic compartment impacts inflammation in the vascular plaques of atherosclerotic mice PLoS One 11 5 2016 e0156364
26 Batth T.S. Tollenaere M.X. Rüther P. Protein aggregation capture on microparticles enables multipurpose proteomics sample preparation Mol Cell Proteomics 18 5 2019 1027 1035 30833379
27 Rappsilber J. Ishihama Y. Mann M. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics Anal Chem 75 3 2003 663 670 12585499
28 Demichev V. Szyrwiel L. Yu F. dia-PASEF data analysis using FragPipe and DIA-NN for deep proteomics of low sample amounts Nat Commun 13 1 2022 3944 35803928
29 Demichev V. Messner C.B. Vernardis S.I. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput Nat Methods 17 1 2020 41 44 31768060
30 Tyanova S. Temu T. Sinitcyn P. The Perseus computational platform for comprehensive analysis of (prote)omics data Nat Methods 13 9 2016 731 740 27348712
31 Luo W. Brouwer C. Pathview: an R/bioconductor package for pathway-based data integration and visualization Bioinformatics 29 14 2013 1830 1831 23740750
32 Luo W. Pant G. Bhavnasi Y.K. Pathview Web: user friendly pathway visualization and data integration Nucleic Acids Res 45 W1 2017 W501 W508 28482075
33 Bresilla D. Habisch H. Pritišanac I. The sex-specific metabolic signature of C57BL/6NRj mice during aging Sci Rep 12 1 2022 21050
34 Veselkov K.A. Lindon J.C. Ebbels T.M. Recursive segment-wise peak alignment of biological (1)h NMR spectra for improved metabolic biomarker recovery Anal Chem 81 1 2009 56 66 19049366
35 Dieterle F. Ross A. Schlotterbeck G. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics Anal Chem 78 13 2006 4281 4290 16808434
36 Wishart D.S. Guo A. Oler E. HMDB 5.0: the human metabolome database for 2022 Nucleic Acids Res 50 D1 2022 D622 D631 34986597
37 Pang Z. Chong J. Zhou G. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights Nucleic Acids Res 49 W1 2021 W388 W396 34019663
38 Chen C. Wang H. Chen B. Pex11a deficiency causes dyslipidaemia and obesity in mice J Cell Mol Med 23 3 2019 2020 2031 30585412
39 Rodrigues T.A. Grou C.P. Azevedo J.E. Revisiting the intraperoxisomal pathway of mammalian PEX7 Sci Rep 5 2015 11806
40 Wells T. Davies J.R. Guschina I.A. Opa3, a novel regulator of mitochondrial function, controls thermogenesis and abdominal fat mass in a mouse model for Costeff syndrome Hum Mol Genet 21 22 2012 4836 4844 22869679
41 Gao R. Li Y. Xu Z. Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease Hepatology 78 6 2023 1800 1815 36651176
42 Yan S. Yang X.F. Liu H.L. Long-chain acyl-CoA synthetase in fatty acid metabolism involved in liver and other diseases: an update World J Gastroenterol 21 12 2015 3492 3498 25834313
43 Boyer-Diaz Z. Aristu-Zabalza P. Andres-Rozas M. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease J Hepatol 74 5 2021 1188 1199 33278455
44 Wettstein G. Luccarini J.M. Poekes L. The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis Hepatol Commun 1 6 2017 524 537 29404476
45 Kochan K. Maslak E. Krafft C. Raman spectroscopy analysis of lipid droplets content, distribution and saturation level in non-alcoholic fatty liver disease in mice J Biophot 8 7 2015 597 609
46 Kuentzel K.B. Bradić I. Akhmetshina A. Defective lysosomal lipolysis causes prenatal lipid accumulation and exacerbates immediately after birth Int J Mol Sci 22 19 2021 10416
47 Staels B. Butruille L. Francque S. Treating NASH by targeting peroxisome proliferator-activated receptors J Hepatol 79 5 2023 1302 1316 37459921
48 Christofides A. Konstantinidou E. Jani C. The role of peroxisome proliferator-activated receptors (PPAR) in immune responses Metabolism 114 2021 154338
